Syndax Pharmaceuticals Inc. (SNDX) is a renowned biopharmaceutical company with a primary focus on the development and commercialization of novel, innovative therapeutics designed to prolong and improve the lives of patients with severe or life-threatening cancers. Situated in Waltham, Massachusetts, the company was launched in 2005, with the ultimate goal of empowering patients in the fight against cancer.
Syndax Pharmaceutical's primary product candidate is Entinostat, an oral, small molecule drug that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated in several phase 1b/2 and 3 clinical trials for various types of solid tumors. The company also develops SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction that is used in the treatment of acute leukemias.
Syndax Pharmaceuticals has collaboration agreements with prestigious research institutions and pharmaceutical giants, such as Genentech, Inc., and National Cancer Institute, continuing to push boundaries in cancer therapy. In addition, the company's intellectual property holds several patents relating to its product candidates, demonstrating a robust and promising research pipeline.
The company's commitment to transforming the lives of cancer patients motivates its push towards the development of next-generation therapies that can effectively tackle advanced cancers. Its pursuits aim to satisfy the unmet medical needs, which have not been adequately covered by the current, conventional therapies.
Throughout the years, Syndax Pharmaceuticals has demonstrated a steadfast commitment to quality, innovation, and patient safety. It aspires to lead the pharma industry in offering comprehensive solutions for serious illnesses and life-threatening conditions. The team of experts at Syndax is driven both by scientific curiosity and a deep desire to bring novel therapies to people who need them the most, upholding the company's objective of ensuring healthier lives and outcomes.
Syndax's approach also encompasses a meticulous and rigorous scientific model that supports the discovery, development, and delivery of innovative cancer treatments. By remaining at the forefront of biopharmaceutical research, Syndax Pharmaceuticals Inc. continues to be a beacon of hope for countless patients and the broader medical community, as cancer's fatal global impact looms as an ever-present challenge.
With its patient-centric strategy, Syndax Pharmaceuticals Inc. continues to make significant strides forward towards pioneering advanced medications and therapeutic solutions that are set to revolutionize the treatment of severe and life-threatening illnesses.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article identifies the top five healthcare and biotech firms based on their year-over-year sales growth in Q3 2026. Recursion Pharmaceuticals led with 258.5% growth, followed by Syndax Pharmaceuticals, Hinge Health, Axsome Therapeutics, and Neurocrine Biosciences. The report details each company's financial performance, key drivers for their sales expansion, and future outlook.
Syndax Pharmaceuticals (SNDX) stock is down significantly year-to-date, prompting questions about its valuation relative to sales, especially after its drug Revuforj won a Prix Galien USA award. While the stock's P/S ratio of 4.6x is below industry averages, it screens as overvalued when considering its specific risk profile and fundamentals. The award for Revuforj suggests investors may be placing a premium on perceived product quality rather than just immediate revenue.
Sell-side analysts have maintained a "Moderate Buy" consensus for Syndax Pharmaceuticals (NASDAQ:SNDX), with an average 12-month price target of $41.80, significantly above its current share price of $13.10. The company reported an 81.9% year-over-year increase in third-quarter revenue to $83.3 million, surpassing estimates, primarily driven by Revuforj and Niktimvo. Despite the strong revenue growth, Syndax remains unprofitable, posting a $0.55-per-share loss, and faces execution risks due to pipeline setbacks and a CFO transition.
Syndax Pharmaceuticals reported a third-quarter EPS miss but exceeded revenue estimates, driven by strong sales of Revuforj and Niktimvo. Despite commercial successes like increased patient starts for Revuforj and higher margin guidance for Niktimvo, pipeline setbacks, including the failure of an IPF trial and a cGVHD delay, have negatively impacted the stock. The company's stock is currently trading near its 52-week low, with investor sentiment remaining negative as the market awaits crucial ASH data.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) after the company's Phase 2 MAXPIRe clinical trial failed to meet its primary endpoint, causing a stock price decline of over 15.7% on October 13, 2026. The firm encourages affected investors to connect with them to assist in the investigation into Syndax's securities.
Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to announce its Q3 2026 earnings after market close on Monday, November 2nd, with analysts anticipating a loss of $0.4848 per share and revenue of $81.91 million. This follows a Q2 2026 performance where the company missed expectations, reporting a $0.55-per-share loss against a $0.45 estimate, though revenue increased by 91.8% year-over-year. Despite trading near its 12-month low, Wall Street maintains a "Moderate Buy" rating with an average price target of $41.80.